Fragrant Prosperity Holdings Ltd Appointment of Director (7338T)

TIDMFPP

RNS Number : 7338T

Fragrant Prosperity Holdings Ltd

29 March 2021

29 March 2021

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN, INTO OR IN THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

Fragrant Prosperity Holdings Limited

("FPP" or the "Company")

Appointment of Director

The Board of Directors of Fragrant Prosperity Holdings Limited, which is seeking an acquisition in several sectors but is currently focused on Cannabis Therapeutics, is pleased to announce the appointment of Dr. Daniel S. Reshef, MD, MPH, PhD to the Board of Directors as a non-executive director. This appointment will become effective as of March 31, 2021.

Dr. Daniel Reshef is a dual Israeli and USA Citizen, currently living in the USA, with strong ties to Israel, Israel medical research centres and a vast array of relationships in the global pharmaceutical sector.

Dr Reshef's extensive career with over twenty five years in drug development encompasses many facets of the Pharmaceutical sector, gained through senior management positions at leading companies such as Hoffman La Roche, Genentech, Bristol Myers Squibb, and in his current capacity as the Therapeutic Area Global Head for a major global Pharmaceutical Company. His scientific experience includes skills in regulatory, medical affairs, drug safety operations and clinical trials epidemiology with leadership experience in early drug development from phase 1 to phase IV, and in multiple therapeutic areas.

Dr. Reshef is a board-certified physician, graduate of the Hebrew University and Hadassah Medical School in Jerusalem, and has earned his MPH and PhD in Epidemiology from Johns Hopkins University.

Craig Marshak Chairman of Fragrant Prosperity commented: "I have personally known and worked with Dr. Daniel Reshef for well over 7 years, and have always been impressed with his world wide experience and skill set. I am delighted to welcome him to the Board and look forward to the additional expertise that he brings to the Company"

Current and previous Directorships within the last 5 years that Dr Reshef holds are set out below:

 
 Current                              Previous 5 years 
 ABTI - Alterola pharmaceuticals 
  - Director 
                                     ----------------- 
 QEBR - Virtual Medical - Director, 
  Vice Chair 
                                     ----------------- 
 Israel Venture Partners - Director 
                                     ----------------- 
 
 
 
 

*Ends*

For more information: http://www.fragrantprosperityholdings.com/

 
 Fragrant Prosperity Holdings 
  Limited 
 Simon Retter/Craig Marshak      [phone] 
 

Broker: Optiva Securities

   Vishal Balasingham                                                       [phone] 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOADKCBKBBKKKNB

(END) Dow Jones Newswires

March 29, 2021 02:00 ET (06:00 GMT)